The global next-generation drug conjugates market is projected to reach $42.55 billion by 2035, according to a MarketsandMarkets analysis released this month, with growth attributed to rising precision medicine adoption, expanding antibody-drug conjugate (ADC) clinical success, and advances in targeted delivery technologies. While the forecast centers on pharmaceutical applications, the underlying delivery science — particularly ligand-directed payload targeting — is increasingly informing how nutraceutical developers approach bioavailability challenges in finished formulations.
Targeted conjugate platforms share conceptual DNA with lipid nanoparticle encapsulation, receptor-mediated uptake, and pH-sensitive release mechanisms that functional ingredient suppliers have been adapting for oral bioavailability optimization. As ADC technology matures in the pharmaceutical pipeline, co-manufacturing partners serving both pharma and supplement sectors are expected to accelerate technology transfer into nutraceutical-grade delivery systems — a trend already visible in liposomal vitamin C and curcumin delivery formats.
The precision medicine tailwind driving ADC adoption also reflects a consumer shift toward personalized health management that is reshaping the functional foods category. Brands positioning products around genetic, microbiome, or biomarker-based protocols are seeing stronger retail performance, and ingredient suppliers are responding by developing standardized extracts and clinically dosed formats that align with individualized health claims. Structure-function claim strategies that reference specific physiological mechanisms — rather than generic wellness language — are gaining traction with operators targeting health-engaged consumers.
For nutraceutical and functional food operators, the $42.55 billion drug conjugate projection serves as a macro signal: investment in targeted delivery infrastructure is intensifying across the broader life sciences supply chain, and GRAS-qualified delivery technologies developed for pharmaceutical precision are increasingly available for adaptation into dietary supplement and functional food matrices. Suppliers already operating in both channels — offering white-label encapsulation or co-manufacturing services — are positioned to bring next-generation delivery formats to market faster than brands building capability in-house. Operators sourcing novel delivery platforms should verify NDI (New Dietary Ingredient) status and confirm that any adapted technology carries robust safety dossiers appropriate for food and supplement applications. Category leaders in personalized nutrition and condition-specific functional formats are already in active dialogue with delivery technology licensors.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.